| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2003;34:2374.)
© 2003 American Heart Association, Inc.
Original Contributions |
From the Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam (I.M. vd M., A.I. d S., A.E.H., M.L.B., A.H., J.C.M.W.), and Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht (M.L.B.), the Netherlands.
Correspondence to Dr J.C.M. Witteman, Erasmus University Medical Center, Department of Epidemiology and Biostatistics, PO Box 1738, 3000 DR Rotterdam, Netherlands. E-mail j.witteman{at}erasmusmc.nl
| Abstract |
|---|
|
|
|---|
Methods The Rotterdam Study is a population-based cohort study of 7983 men and women
55 years of age. Carotid plaques and intima-media thickness were assessed by ultrasound, aortic atherosclerosis by x-ray, and lower-extremity atherosclerosis by the ankle-arm index. Data on progression of atherosclerosis over an average period of 6.5 years were available for 3409 participants. Associations of established cardiovascular risk factors with mild, moderate, and severe progression of atherosclerosis were investigated through multinomial regression analysis.
Results Age, smoking, total cholesterol, and systolic blood pressure and/or hypertension were strong, independent predictors of moderate and severe progression of atherosclerosis at multiple sites. Diabetes mellitus predicted only severe progression of atherosclerosis. Associations of sex with progression of atherosclerosis were remarkably modest.
Conclusions Age, smoking, total cholesterol, and systolic blood pressure and/or hypertension strongly predict progression of extracoronary atherosclerosis in the elderly, but sex remarkably does not. These results emphasize the need for prevention of progression of extracoronary atherosclerotic disease in men and women alike.
Key Words: atherosclerosis cohort studies gender risk factors
| Introduction |
|---|
|
|
|---|
Although the amount of atherosclerosis at 1 point in time is a reflection of lifelong accumulation of atherosclerotic lesions, changes in the extent of atherosclerosis with time give important information about whether, and at what rate, atherosclerotic disease advances. Several studies have reported associations of cardiovascular risk factors with progression of atherosclerosis.7,9,10 However, none of these studies has yet investigated whether the associations of cardiovascular risk factors with progression of atherosclerosis are consistent across different vascular beds.
Within the Rotterdam Study, a prospective, population-based cohort study among men and women
55 years of age, various noninvasive methods were used to assess progression of atherosclerosis over an average period of 6.5 years. We investigated associations of cardiovascular risk factors with progression of atherosclerosis measured at multiple sites in the arterial tree.
| Materials and Methods |
|---|
|
|
|---|
55 years of age. Its aim is to investigate the incidence and determinants of chronic disabling diseases. At phase 1 (baseline; 1990 to 1993), all inhabitants of a suburb of the city of Rotterdam who were
55 years of age were invited to participate in an extensive home interview and 2 visits to the research center. The overall response rate was 78%. Phase 3 was conducted in a similar way from 1997 to 1999. Between phases 1 and 3, 25% of the participants had died, and 0.4% were lost to follow-up. Because at phase 2 only a small part of the atherosclerosis measurements were performed, data from this phase were not included in the present study. The Medical Ethics Committee of the Erasmus University Medical Center approved the Rotterdam Study, and written informed consent was obtained from all participants.11 Of the 7983 participants of the Rotterdam Study, 6505 had never experienced a myocardial infarction, stroke, or revascularization procedure before phase 3. For 6145 of these participants, the extent of atherosclerosis was assessed at baseline at least at 1 site in the arterial tree. For 3506 participants, information on at least 1 measure of atherosclerosis at phase 3 of the Rotterdam Study was also available. Subjects with missing data on >2 cardiovascular risk factors investigated in the present study were excluded (n=97), resulting in a study population of 3409 participants.
Clinical Characteristics
At baseline, a trained investigator visited all participants at home and collected information using a computerized questionnaire. The obtained information included current health status, medical history, drug use, and smoking behavior. Additionally, during 2 visits to the research center, established cardiovascular risk factors were measured, and nonfasting blood samples were obtained.12 Obesity was defined as body mass index (BMI)
30.0 kg/m2 and/or waist circumference
102 cm in men or
88 cm in women.13 We defined hypertension as systolic blood pressure
160 mm Hg, diastolic blood pressure
100 mm Hg, and/or use of blood pressurelowering medication with indication of hypertension at phase 1 of the Rotterdam Study. Hypercholesterolemia was defined as serum total cholesterol
6.5 mmol/L and/or the use of cholesterol-lowering medication at phase 1. We defined diabetes mellitus as a random or postload serum glucose level
11.1 mmol/L and/or the use of blood glucoselowering medication.
Measures of Atherosclerosis
The extent of atherosclerosis was assessed at phases 1 and 3 of the Rotterdam Study by measuring carotid plaques, carotid intima-media thickness (IMT), aortic atherosclerosis, and lower-extremity atherosclerosis (as indicated by the AAI). Progression of atherosclerosis was divided into 4 categories (no, mild, moderate, severe), except for progression of carotid plaques (3 categories: no, moderate, severe) because of the sample distribution of this measure of progression of atherosclerosis. To be able to compare the different associations of a particular cardiovascular risk factor with progression of the different measures of atherosclerosis, we tried to categorize progression of atherosclerosis in such a way that a specific category (eg, the severe category) included a comparable percentage of the study sample for all of the 4 measures.
Carotid Atherosclerosis
Ultrasonography of both carotid arteries was performed with a 7.5-MHz linear-array transducer and a duplex scanner (ATL UltraMark IV, Advanced Technology Laboratories). The common carotid artery, carotid bifurcation, and internal carotid artery were examined on both the left and right sides for the presence of plaques as described before.2 A weighted plaque score ranging from 0 to 6 was computed by adding the number of sites at which a plaque was detected, dividing by the total number of sites for which an ultrasonographic image was available, and multiplying by 6 (the maximum number of sites). Progression of carotid plaques was computed by subtracting the plaque score at phase 1 from the plaque score at phase 3. Subjects for whom data on the presence of plaques were not available for at least 4 of the 6 sites examined both at phase 1 and at phase 3 were excluded from analyses. We defined no, moderate, and severe progression of carotid plaques as a change in plaque score of 0, 1 to 2, or
3 points, respectively. Subjects with a decrease in plaque score were added to the group with no progression because we considered this to be due mainly to measurement error.
Common carotid IMT was determined as the average of near- and far-wall measurements, and the average of left and right common carotid IMT was computed.2 Progression of IMT was defined as the difference in mean IMT between phase 3 and phase 1. Subjects were divided into categories of progression of IMT on the basis of their ranking in the sample distribution. Subjects with an increase in IMT below the 30th percentile of the distribution of all subjects with an increase in IMT were considered to have no progression of IMT. Subjects with an increase in IMT above the 30th, 60th, and 90th percentiles of the sample distribution were considered to have mild, moderate, and severe progression of IMT, respectively. We added subjects for whom we found a decrease in IMT to the group with no progression. Because of the limited availability of ultrasonographers at the end of 1992 and in 1993, ultrasound data are missing for some of the subjects who visited the Rotterdam Study research center at phase 1.
Aortic Atherosclerosis
Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta on a lateral abdominal film.7 For progression of aortic atherosclerosis, baseline and follow-up films were examined in pairs. Progression was scored on a graded scale (with scores of 0 to 4 corresponding to 0,
1, 1 to 2.5, 2.5 to 4.9, and
5.0 cm progression, respectively). None of the participants showed a decrease in the extent of aortic atherosclerosis. We defined no, mild, moderate, and severe progression of aortic atherosclerosis as a progression score of 0, 1, 2, and >2, respectively.
Lower-Extremity Atherosclerosis
Systolic blood pressure at the ankles (posterior tibial artery) was measured in the supine position with a random-zero sphygmomanometer and an 8-MHz continuous-wave Doppler probe (Huntleigh 500D, Huntleigh Technology). We computed the ratio of the systolic blood pressure at the ankle to the systolic blood pressure at the arm to obtain the AAI. Because arterial rigidity prevents arterial compression and therefore will lead to spuriously high values of the AAI, an AAI >1.50 was considered invalid.12 Progression of lower-extremity atherosclerosis was computed by subtracting the AAI at phase 1 from the AAI at phase 3. For the analyses, we used the leg with the largest decrease in AAI. Subjects with a decrease in AAI below the 30th percentile of the sample distribution of all subjects with a decrease in AAI were considered to have no progression of lower-extremity atherosclerosis. Subjects with a decrease in AAI above the 30th, 60th and 90th percentiles of the sample distribution were considered to have mild, moderate, and severe progression of lower-extremity atherosclerosis, respectively. We added subjects for whom we found an increase in AAI to the group with no progression. Data on progression of carotid plaques, IMT, aortic atherosclerosis, and lower-extremity atherosclerosis were available for 2366, 2622, 2687, and 2756 participants, respectively.
Statistical Analyses
For subjects with missing data on clinical characteristics measured on a continuous scale, we imputed the population mean. Using multinomial logistic regression analysis, we examined the association of cardiovascular risk factors with mild, moderate, and severe progression of atherosclerosis. Analyses with age as the determinant were adjusted for sex and duration of follow-up. Analyses with sex as the determinant were adjusted for age, duration of follow-up, andto account for the large percentage of ever smokers (84.4%) in mencurrent and past smoking. Analyses with all other cardiovascular risk factors as the determinant were adjusted for age, sex, duration of follow-up, current and past smoking, BMI, waist-to-hip ratio, total and high-density lipoprotein (HDL) cholesterol, systolic and diastolic blood pressures, diabetes mellitus, and use of cholesterol-lowering and blood pressurelowering medication at any point in time between phase 1 and phase 3. Analyses on the association of hypertension with progression of atherosclerosis did not include the variables systolic and diastolic blood pressures, and subjects on blood pressurelowering medication with an indication other than hypertension were excluded.
| Results |
|---|
|
|
|---|
|
Current smoking was the strongest predictor of progression of carotid plaques (Table 2). Age, total cholesterol, and systolic blood pressure were also strong, independent predictors of both moderate and severe progression. Men seemed to be at a higher risk of carotid plaque progression, but the odds ratio (OR) for severe progression was not statistically significant. Past smoking and diabetes mellitus only, but strongly so, predicted severe progression of carotid plaques. BMI and waist-to-hip ratio had ORs in opposite directions, especially in their association with moderate progression of carotid plaques.
|
Age and BMI were strong predictors of mild (only BMI), moderate, and severe progression of carotid IMT (Table 3). Sex (inverse association), current (borderline) and past smoking, systolic blood pressure, and hypertension (borderline) were significant predictors of severe but not mild and moderate progression of carotid IMT. Other cardiovascular risk factors did not predict progression of carotid IMT.
|
Table 4 shows that age, smoking habits, total cholesterol, systolic blood pressure, and hypertension were all strong predictors of mild, moderate, and severe progression of aortic atherosclerosis. Sex predicted only mild progression. For BMI and diastolic blood pressure, there was a protective effect, as there was for HDL cholesterol, but the OR for severe progression was not statistically significant for HDL cholesterol. Diabetes mellitus was a strong predictor of severe progression of aortic atherosclerosis.
|
Current smoking was the strongest predictor of mild, moderate, and severe progression of lower-extremity atherosclerosis (Table 5). Age, total cholesterol, and hypertension also predicted moderate and severe progression of lower-extremity atherosclerosis. Sex was a borderline significant predictor of severe progression of lower-extremity atherosclerosis, but the association with moderate progression was inverse. Diabetes mellitus predicted only severe progression. For BMI and HDL cholesterol, there was a protective effect.
|
When we excluded subjects with a decrease in carotid plaque score or IMT or an increase in AAI, results were similar to those presented in the tables. In subgroup analyses stratified by sex, we found no major differences between men and women that were consistent across the 4 measures of atherosclerosis. Moreover, no statistically significant interactions between risk factors were consistently found. We did not find evidence of a nonlinear association for any of the associations of continuous variables with progression of atherosclerosis, apart from a modest exponential association of age with progression of carotid IMT (overall value for quadratic term, P=0.08; for moderate and severe progression, P=0.07 and 0.03, respectively, adjusted for sex and duration of follow-up) and with progression of aortic atherosclerosis (overall P=0.08; for mild and moderate progression, P=0.02 and 0.03, respectively). Addition of the quadratic term for age to the multivariate models did not change any of the ORs associated with the other cardiovascular risk factors.
Finally, the Figure shows ORs for severe progression of all measures of atherosclerosis associated with current smoking, obesity, hypercholesterolemia, hypertension, and diabetes mellitus.
|
| Discussion |
|---|
|
|
|---|
The strength of the present study, a relatively large cohort study in a very homogeneous population of elderly people, is the assessment of progression of atherosclerosis at multiple sites. Still, several methodological issues of this study need to be considered. First, subjects with the most severe atherosclerosis at baseline are more likely to have died and therefore are not included in the present study. Although this may have somewhat limited the range of baseline levels of atherosclerosis, it does not affect the validity of the risk estimates. Second, because we defined categories of progression of carotid IMT and the AAI according to percentiles, one should note that the distinction between these categories is not based on clear-cut clinical differences in progression of atherosclerosis. Moreover, our definitions of no, mild, moderate, and severe progression of atherosclerosis depend on the distribution of progression of atherosclerosis within our study population and may therefore be different in other populations. Third, baseline levels of atherosclerosis may influence the association between cardiovascular risk factors and progression of atherosclerosis. However, because of the phenomenon of regression to the mean as a result of measurement error, adjusting for baseline atherosclerosis may introduce bias that leads to an overestimation of the risk estimates.14 For categorical variables, no statistical model has yet been developed to adjust for baseline values without introducing bias. For continuous variables, both the Atherosclerosis Risk in Communities study and the Cardiovascular Health Study, investigating associations between cardiovascular risk factors and progression of IMT, showed that not adjusting for baseline levels of atherosclerosis gave similar results as adjusting for baseline atherosclerosis while at the same time taking measurement error into account.15,16 In the present study, we did not adjust for baseline levels of atherosclerosis. Finally, although the measures of atherosclerosis used in the present study were strongly associated with coronary calcification,5 differences between these measures exist. For the carotid plaque score, we measured distinct atherosclerotic lesions, and radiographically assessed calcification of the abdominal aorta has been shown to specifically represent advanced intimal atherosclerosis.17 However, changes in IMT and AAI may also be due in part to nonatherosclerotic processes such as fibromuscular hypertrophy, which causes modest increases in IMT, and hemodynamic factors and vascular stiffness, which may influence AAI.
Although for coronary atherosclerosis differences between men and women are pronounced,18 we report remarkably modest and inconsistent associations between sex and progression of extracoronary atherosclerosis. This finding is in accordance with the fact that the difference between men and women is much smaller for the incidence of stroke than for the incidence of myocardial infarction.19,20 Moreover, we have previously shown that the prevalences of peripheral arterial disease in men and women participating in the Rotterdam Study are similar.12 It should be kept in mind that these findings could be different in populations with premenopausal women, in whom the protective effects of endogenous estrogens may lead to a slower rate of progression of atherosclerosis than in men.21 However, because most clinical events related to atherosclerotic disease occur in postmenopausal women, the results from the present study stress the importance of prevention of progression of extracoronary atherosclerotic disease in both men and women alike.
Although we used a standardized protocol for the measurement of IMT both at baseline and at the follow-up visit, a relatively large part of the computed change in IMT over the years may be distorted by measurement error. This may explain why only a few cardiovascular risk factors (smoking habits, BMI, and systolic blood pressure) were significant predictors of progression of carotid IMT, whereas associations of traditional cardiovascular risk factors with progression of carotid plaques were much stronger. Both more precise methods to measure progression of carotid IMT and the assessment of not only the presence but also the volume of carotid plaques will further improve our ability to determine the rate of progression of carotid atherosclerosis.
This population-based study shows that age, smoking behavior, total cholesterol, and systolic blood pressure and/or hypertension are strong predictors of progression of atherosclerosis, regardless of the site of measurement. Sex is not an important risk indicator for progression of extracoronary atherosclerotic disease in men and women
55 years of age.
| Acknowledgments |
|---|
Received March 26, 2003; revision received May 23, 2003; accepted June 11, 2003.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
I. Kardys, R. Vliegenthart, M. Oudkerk, A. Hofman, and J. C. M. Witteman The Female Advantage in Cardiovascular Disease: Do Vascular Beds Contribute Equally? Am. J. Epidemiol., August 15, 2007; 166(4): 403 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mupparapu and I. H. Kim Calcified carotid artery atheroma and stroke: A systematic review J Am Dent Assoc, April 1, 2007; 138(4): 483 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Bots, D. Baldassarre, A. Simon, E. de Groot, D. H. O'Leary, W. Riley, J. J. Kastelein, and D. E. Grobbee Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur. Heart J., February 2, 2007; 28(4): 398 - 406. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Harloff, C. Strecker, M. Reinhard, M. Kollum, M. Handke, M. Olschewski, C. Weiller, and A. Hetzel Combined Measurement of Carotid Stiffness and Intima-Media Thickness Improves Prediction of Complex Aortic Plaques in Patients With Ischemic Stroke Stroke, November 1, 2006; 37(11): 2708 - 2712. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. de Voogd, R. C. W. Wolfs, N. M. Jansonius, J. C. M. Witteman, A. Hofman, and P. T. V. M. de Jong Atherosclerosis, C-reactive protein, and risk for open-angle glaucoma: the rotterdam study. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3772 - 3776. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Chade, O. P. Mushin, X. Zhu, M. Rodriguez-Porcel, J. P. Grande, S. C. Textor, A. Lerman, and L. O. Lerman Pathways of Renal Fibrosis and Modulation of Matrix Turnover in Experimental Hypercholesterolemia Hypertension, October 1, 2005; 46(4): 772 - 779. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. van Dijk, N. D. Prins, S. E. Vermeer, H. A. Vrooman, A. Hofman, P. J. Koudstaal, and M. M.B. Breteler C-Reactive Protein and Cerebral Small-Vessel Disease: The Rotterdam Scan Study Circulation, August 9, 2005; 112(6): 900 - 905. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Bots, D. E. Grobbee, A. Hofman, and J. C.M. Witteman Common Carotid Intima-Media Thickness and Risk of Acute Myocardial Infarction: The Role of Lumen Diameter Stroke, April 1, 2005; 36(4): 762 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W. Asselbergs, A. M. van Roon, H. L. Hillege, P. E. de Jong, R. O.B. Gans, A. J. Smit, W. H. van Gilst, and on behalf of the PREVEND IT Investigators Effects of Fosinopril and Pravastatin on Carotid Intima-Media Thickness in Subjects With Increased Albuminuria Stroke, March 1, 2005; 36(3): 649 - 653. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Beishuizen, M. A. van de Ree, J. W. Jukema, J. T. Tamsma, J. C. M. van der Vijver, A. E. Meinders, H. Putter, and M. V. Huisman Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease Diabetes Care, December 1, 2004; 27(12): 2887 - 2892. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |